ESR1 and breast carcinoma: Albeit a lower risk of tumor recurrence compared to other molecular subtypes, around 20% of ER+ patients may develop local/distant recurrences after treatment, and younger patients (age≤ 40 years) are found to have a much higher 5-year breast cancer specific-mortality rate (BCSM), mounting up to 40%, than elder patients [12].